Ifergan Igal, Wosik Karolina, Cayrol Romain, Kébir Hania, Auger Chantale, Bernard Monique, Bouthillier Alain, Moumdjian Robert, Duquette Pierre, Prat Alexandre
Neuroimmunology Laboratory, Center for Research on Brain Diseases, Centre Hospitalier de l'Université de Montreal, CHUM Research Center, Quebec, Canada.
Ann Neurol. 2006 Jul;60(1):45-55. doi: 10.1002/ana.20875.
Dysregulation of the blood-brain barrier (BBB) and transendothelial migration of immune cells are among the earliest central nervous system changes partaking in lesion formation in both multiple sclerosis (MS) and its early clinical form, the clinically isolated syndrome. Evidence for the anti-inflammatory effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors within the central nervous system arose from studies demonstrating that statins improve clinical signs in the animal model of MS and reduce the number of gadolinium-enhancing lesions in MS.
We sought to describe the impact of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor treatment on the physiology and immunology of human BBB-derived endothelial cells (ECs).
We demonstrate that lovastatin and simvastatin induce a 50 to 60% reduction in the diffusion rates of bovine serum albumin and [(14)C]-sucrose across human BBB-ECs in vitro through abrogation of isoprenylation processes, but independent of the expression of the tight junction molecules occludin, VE-cadherin, JAM-1, zonula occluden-1, and zonula occluden-2. Simvastatin and lovastatin were equipotent in reducing BBB permeability in vitro, with median effective concentration (EC(50)) of 9.5 x 10(-8) and 1.0 x 10(-7)M, respectively. We further demonstrate that lovastatin and simvastatin treatment of BBB-ECs significantly restricts the migration of clinically isolated syndrome-derived and MS-derived monocytes and lymphocytes across the human BBB in vitro, through a specific reduction in the secretion of the chemokines monocyte chemotactic protein-1/CCL2 and interferon-gamma-inducible protein-10/CXCL10 by BBB-ECs.
Our data parallel the previously reported magnetic resonance imaging-based radiological findings and suggest an effect of statins that could be beneficial in early MS, restricting the diffusion of molecular tracers and the migration of immune cells across the human BBB.
血脑屏障(BBB)功能失调及免疫细胞的跨内皮迁移是多发性硬化(MS)及其早期临床形式——临床孤立综合征中参与病变形成的最早的中枢神经系统变化。3-羟基-3-甲基戊二酰辅酶A还原酶抑制剂在中枢神经系统内具有抗炎作用的证据源于多项研究,这些研究表明他汀类药物可改善MS动物模型的临床症状,并减少MS中钆增强病灶的数量。
我们试图描述3-羟基-3-甲基戊二酰辅酶A还原酶抑制剂治疗对人BBB来源的内皮细胞(ECs)的生理学和免疫学的影响。
我们证明,洛伐他汀和辛伐他汀通过废除异戊二烯化过程,使牛血清白蛋白和[¹⁴C] -蔗糖在体外跨人BBB-ECs的扩散速率降低50%至60%,但与紧密连接分子闭合蛋白、血管内皮钙黏蛋白、连接黏附分子-1、闭合小环蛋白-1和闭合小环蛋白-2的表达无关。辛伐他汀和洛伐他汀在体外降低BBB通透性方面效果相当,中位有效浓度(EC₅₀)分别为9.5×10⁻⁸和1.0×10⁻⁷M。我们进一步证明,用洛伐他汀和辛伐他汀处理BBB-ECs可显著限制临床孤立综合征来源的和MS来源的单核细胞和淋巴细胞在体外跨人BBB的迁移,这是通过BBB-ECs分泌趋化因子单核细胞趋化蛋白-1/CCL2和干扰素-γ诱导蛋白-10/CXCL10的特异性减少实现的。
我们的数据与先前报道的基于磁共振成像的放射学结果一致,并提示他汀类药物的一种可能对早期MS有益的作用,即限制分子示踪剂的扩散以及免疫细胞跨人BBB的迁移。